Aldehyde dehydrogenase 2 in sporadic Parkinson's disease

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Michel, Tanja Maria ^a   Käsbauer, Ludwig ^b   Gsell, Wieland ^b   Jecel, Julia ^c   Sheldrick, Abigail Jane ^a   Cortese, Miriam ^d   Nickl Jockschat, Thomas ^a   Grünblatt, Edna ^e   Riederer, Peter ^b,f  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c DANUBE HOSPITAL   (Austria)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f Visiting Researcher at Department of Cognitive Brain Sciences NCGG   (Japan)

Author keywords

Aldehyde dehydrogenase 2; Aldehyde toxicity; Mitochondrial defect; Oxidative stress; Parkinson's disease

Indexed keywords

ALDEHYDE DEHYDROGENASE ISOENZYME 2;

AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME LOCALIZATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; LEWY BODY; MALE; MITOCHONDRIAL MEMBRANE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA;

ALDEHYDE DEHYDROGENASE 2; ALDEHYDE TOXICITY; MITOCHONDRIAL DEFECT; OXIDATIVE STRESS; PARKINSON'S DISEASE;

ALDEHYDE DEHYDROGENASE; HUMANS; PARKINSON DISEASE;

EID: 84887895403     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70018-X     Document Type: Article

References (30)

1. Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm 2004, 111:1543-1573.
2. Sian-Hülsmann J, Mandel S, Youdim MB, Riederer P The relevance of iron in the pathogenesis of Parkinson's disease. J Neurochem 2011, 118:939-957.
3. Koutsilieri E, Scheller C, Grünblatt E, Nara K, Li J, Riederer P Free radicals in Parkinson's disease. J Neurol 2002, 249:1-5.
4. Michel TM, Gsell W, Käsbauer L, Tatschner T, Sheldrick AJ, Neuner I, et al. Increased activity of mitochondrial aldehyde dehydrogenase (ALDH) in the putamen of individuals with Alzheimer's disease: a human post-mortem study. J Alzheimers Dis 2010, 19:1295-1301.
5. Harada S, Agarwal DP, Goedde HW Electrophoretic and biochemical studies of human aldehyde dehydrogenase isozymes in various tissues. Life Sci 1980, 26:1773-1780.
6. Nagatsu T, Sawada M Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. J Neural Transm Suppl 2006, 71:53-65.
7. Molochnikov L, Rabey JM, Dobronevsky E, Bonuccelli U, Ceravolo R, Frosini D, et al. A molecular signature in blood identifies early Parkinson's disease. Mol Neurodegener 2012, 7:26.
8. Goldstein DS, Sullivan P, Holmes C, Kopin IJ, Basile MJ, Mash DC Catechols in post-mortem brain of patients with Parkinson disease. Eur J Neurol 2011, 18:703-710.
9. Jinsmaa Y, Florang VR, Rees JN, Mexas LM, Eckert LL, Allen EM, et al. Dopamine-derived biological reactive intermediates and protein modifications: Implications for Parkinson's disease. Chem Biol Interact 2011, 192:118-121.
10. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 2003, 989:205-213.
11. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 2012, 7:e31522.
12. Galter D, Buervenich S, Carmine A, Anvret M, Olson L ALDH1 mRNA: presence in human dopamine neurons and decreases in substantia nigra in Parkinson's disease and in the ventral tegmental area in schizophrenia. Neurobiol Dis 2003, 14:637-647.
13. Grünblatt E, Zehetmayer S, Jacob CP, Müller T, Jost WH, Riederer P Pilot study: peripheral biomarkers for diagnosing sporadic Parkinson's disease. J Neural Transm 2010, 117:1387-1393.
14. Mandel SA, Fishman-Jacob T, Youdim MBH Genetic reduction of the E3 ubiquitin ligase element, SKP1A and environmental manipulation to emulate cardinal features of Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl 1):S177-S179.
15. Gsell W, Lange KW, Pfeuffer R, Heckers S, Heinsen H, Senitz D, et al. How to run a brain bank. A report from the Austro-German brain bank. J Neural Transm Suppl 1993, 39:31-70.
16. Bradford MM A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
17. Ryzlak MT, Pietruszko R Purification and characterization of aldehyde dehydrogenase from human brain. Arch Biochem Biophys 1987, 255:409-418.
18. Westerlund M, Belin AC, Felder MR, Oson L, Galter D High and complementary expression patterns of alcoholic and aldehyde dehydrogenases in the gastrointestinal tract: implications for Parkinson's disease. FEBS J 2007, 274:1212-1223.
19. Maring JA, Deitrich RA, Little R Partial purification and properties of human brain aldehyde dehydrogenases. J Neurochem 1985, 45:1903-1910.
20. Lamensdorf I, Eisenhofer G, Harvey-White J, Nechustan A, Kirk K, Kopin IJ 3,4-Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC12 cells. Brain Res 2000, 868:191-201.
21. Yoval-Sánchez B, Rodriguez-Zavala JS Differences in susceptibility to inactivation of human aldehyde dehydrogenases by lipid peroxidation byproducts. Chem Res Toxicol 2012, 25:722-729.
22. Song BJ, Abdelmegeed MA, Yoo SH, Kim BJ, Jo SA, Jo I, et al. Post-translational modifications of mitochondrial aldehyde dehydrogenase and biomedical implications. J Proteomics 2011, 74:2691-2702.
23. Budas GR, Disatnik MH, Chen CH, Mochly-Rosen D Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCe) knockout mice. J Moll Cell Cardiol 2010, 48:757-764.
24. Münch G, Lüth HJ, Wong A, Arendt T, Hirsch E, Ravid R, et al. Crosslinking of alpha-synuclein by advanced glycation endproducts - an early pathophysiological step in Lewy body formation?. J Chem Neuroanat 2000, 20:253-257.
25. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, et al. Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Biol. Med 2001, 30:924-931.
26. Goldstein DS, Sullivan P, Holmes C, Miller GW, Alter S, Strong R, et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J Neurochem 2013, 126:591-603.
27. Suzuki K, Mizuno Y, Yoshida M Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-like compounds on mitochondrial respiration. Adv Neurol 1990, 53:215-218.
28. Rooke N, Li DJ, Li J, Keung WM The mitochondrial monoamine oxidase-aldehyde dehydrogenase pathway: a potential site of action of daidzin. J Med Chem 2000, 43:4169-4179.
29. Wey MC, Fernandez E, Martinez PA, Sullivan P, Goldstein DS, Strong R Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease. PLoS One 2012, 7:e31522.
30. Fitzmaurice AG, Rhodes SL, Lulla A, Murphy NP, Lam HA, O'Donnell KC, et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc Natl Acad Sci U S A 2013, 110:636-641.